WO2007040912A3 - Human monoclonal antibodies to activin receptor-like kinase-1 - Google Patents

Human monoclonal antibodies to activin receptor-like kinase-1 Download PDF

Info

Publication number
WO2007040912A3
WO2007040912A3 PCT/US2006/035096 US2006035096W WO2007040912A3 WO 2007040912 A3 WO2007040912 A3 WO 2007040912A3 US 2006035096 W US2006035096 W US 2006035096W WO 2007040912 A3 WO2007040912 A3 WO 2007040912A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
alk
relates
kinase
activin receptor
Prior art date
Application number
PCT/US2006/035096
Other languages
French (fr)
Other versions
WO2007040912A2 (en
Inventor
Michael Aidan North
Karin Kristina Amundson
Vahe Bedian
Shelley Sims Belouski
Dana Dan Hu-Lowe
Xin Jiang
Shannon Marie Karlicek
Sirid-Aimee Kellermann
James Arthur Thomson
Jianying Wang
Grant Raymond Wickman
Jingchuan Zhang
Original Assignee
Amgen Fremont Inc
Pfizer
Michael Aidan North
Karin Kristina Amundson
Vahe Bedian
Shelley Sims Belouski
Dana Dan Hu-Lowe
Xin Jiang
Shannon Marie Karlicek
Sirid-Aimee Kellermann
James Arthur Thomson
Jianying Wang
Grant Raymond Wickman
Jingchuan Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37906640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007040912(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to KR1020087006587A priority Critical patent/KR101390127B1/en
Priority to RS20080103A priority patent/RS54393B1/en
Priority to BRPI0615766-1A priority patent/BRPI0615766A2/en
Priority to MEP-2008-812A priority patent/ME00501B/en
Priority to AP2013006963A priority patent/AP2013006963A0/en
Priority to DK06824915.0T priority patent/DK1933871T3/en
Priority to CN200680041490.3A priority patent/CN101517068B/en
Priority to EP06824915.0A priority patent/EP1933871B1/en
Priority to AU2006297571A priority patent/AU2006297571B2/en
Priority to KR1020137033726A priority patent/KR101536506B1/en
Priority to ES06824915T priority patent/ES2421146T3/en
Priority to AP2008004388A priority patent/AP2723A/en
Priority to EA200800759A priority patent/EA018453B1/en
Application filed by Amgen Fremont Inc, Pfizer, Michael Aidan North, Karin Kristina Amundson, Vahe Bedian, Shelley Sims Belouski, Dana Dan Hu-Lowe, Xin Jiang, Shannon Marie Karlicek, Sirid-Aimee Kellermann, James Arthur Thomson, Jianying Wang, Grant Raymond Wickman, Jingchuan Zhang filed Critical Amgen Fremont Inc
Priority to PL06824915T priority patent/PL1933871T3/en
Priority to NZ566774A priority patent/NZ566774A/en
Priority to EP18170945.2A priority patent/EP3381945B1/en
Priority to MYPI20080556A priority patent/MY164457A/en
Priority to CA2621371A priority patent/CA2621371C/en
Priority to SI200631626T priority patent/SI1933871T1/en
Priority to KR1020137007712A priority patent/KR101536487B1/en
Priority to JP2008530231A priority patent/JP5161777B2/en
Publication of WO2007040912A2 publication Critical patent/WO2007040912A2/en
Priority to IL189642A priority patent/IL189642A/en
Priority to TNP2008000080A priority patent/TNSN08080A1/en
Priority to NO20081718A priority patent/NO20081718L/en
Publication of WO2007040912A3 publication Critical patent/WO2007040912A3/en
Priority to IL218429A priority patent/IL218429A0/en
Priority to CR20130351A priority patent/CR20130351A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to the extracellular doman (ECD) of activin receptor-like kinase-1 (ALK-1) and that function to abrogate the ALK-1/TGF-beta-1/Smad1 signaling pathway. The invention also relates to heavy and light chain immunoglobulins derived from human anti-ALK-1 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of makind human anti-ALK-1 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
PCT/US2006/035096 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1 WO2007040912A2 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
JP2008530231A JP5161777B2 (en) 2005-09-07 2006-09-06 Human monoclonal antibody against activin receptor-like kinase-1
NZ566774A NZ566774A (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1
PL06824915T PL1933871T3 (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1
MEP-2008-812A ME00501B (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1
RS20080103A RS54393B1 (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1
DK06824915.0T DK1933871T3 (en) 2005-09-07 2006-09-06 HUMAN MONOCLONAL ANTIBODIES AGAINST ACTIVIN RECEPTOR LIKE KINASE-1
CN200680041490.3A CN101517068B (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1
EP06824915.0A EP1933871B1 (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1
AU2006297571A AU2006297571B2 (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1
KR1020137033726A KR101536506B1 (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1
ES06824915T ES2421146T3 (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor type kinase-1
EP18170945.2A EP3381945B1 (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1
EA200800759A EA018453B1 (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1 and use thereof
KR1020087006587A KR101390127B1 (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1
BRPI0615766-1A BRPI0615766A2 (en) 2005-09-07 2006-09-06 human monoclonal antibodies to acitivine receptor-like kinase-1
AP2013006963A AP2013006963A0 (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like Kinase-1
AP2008004388A AP2723A (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activ in receptor-like Kinase-1
MYPI20080556A MY164457A (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1
CA2621371A CA2621371C (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1
SI200631626T SI1933871T1 (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1
KR1020137007712A KR101536487B1 (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1
TNP2008000080A TNSN08080A1 (en) 2005-09-07 2008-02-21 Human monoclonal antibodies to activin receptor-like kinase-1
IL189642A IL189642A (en) 2005-09-07 2008-02-21 Human monoclonal antibodies to activin receptor-like kinase 1
NO20081718A NO20081718L (en) 2005-09-07 2008-04-07 Human monoclonal antibodies to activin receptor-like kinase-1
IL218429A IL218429A0 (en) 2005-09-07 2012-03-01 Human monoclonal antibodies to activin receptor-like kinase-1
CR20130351A CR20130351A (en) 2005-09-07 2013-07-19 HUMAN MONOCLONAL ANTIBODIES FOR KINASE-1 ACTIVINE RECEPTOR TYPE (DIVIISIONAL 9819)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71529205P 2005-09-07 2005-09-07
US60/715,292 2005-09-07

Publications (2)

Publication Number Publication Date
WO2007040912A2 WO2007040912A2 (en) 2007-04-12
WO2007040912A3 true WO2007040912A3 (en) 2009-04-30

Family

ID=37906640

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/035096 WO2007040912A2 (en) 2005-09-07 2006-09-06 Human monoclonal antibodies to activin receptor-like kinase-1

Country Status (41)

Country Link
US (3) US7537762B2 (en)
EP (4) EP1933871B1 (en)
JP (3) JP5161777B2 (en)
KR (3) KR101536506B1 (en)
CN (2) CN107056943B (en)
AP (2) AP2013006963A0 (en)
AR (2) AR055152A1 (en)
AU (1) AU2006297571B2 (en)
BR (1) BRPI0615766A2 (en)
CA (1) CA2621371C (en)
CL (1) CL2010000096A1 (en)
CR (3) CR9819A (en)
CY (1) CY1120794T1 (en)
DK (3) DK1933871T3 (en)
DO (1) DOP2006000195A (en)
EA (2) EA201300320A1 (en)
ES (3) ES2681656T3 (en)
GE (1) GEP20125398B (en)
GT (1) GT200600406A (en)
HK (2) HK1169999A1 (en)
HN (1) HN2006031275A (en)
HU (2) HUE025608T2 (en)
IL (2) IL189642A (en)
LT (1) LT2960253T (en)
MA (1) MA29843B1 (en)
ME (1) ME00501B (en)
MY (1) MY164457A (en)
NL (1) NL1032452C2 (en)
NO (1) NO20081718L (en)
NZ (1) NZ566774A (en)
PE (1) PE20080035A1 (en)
PL (3) PL2960253T3 (en)
PT (3) PT1933871E (en)
RS (1) RS54393B1 (en)
SI (3) SI1933871T1 (en)
TN (1) TNSN08080A1 (en)
TW (5) TWI541253B (en)
UA (1) UA94060C2 (en)
UY (1) UY29783A1 (en)
WO (1) WO2007040912A2 (en)
ZA (1) ZA200802971B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
US7897581B2 (en) * 2005-02-24 2011-03-01 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
TWI541253B (en) * 2005-09-07 2016-07-11 艾默根佛蒙特有限公司 Human monoclonal antibodies to activin receptor-like kinase-1
AU2007213791A1 (en) * 2006-02-10 2007-08-16 Nerviano Medical Sciences S.R.L. Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic
AU2012265564B2 (en) * 2006-09-08 2016-05-26 Amgen Inc Anti-activin A antibodies and uses thereof
CL2007002567A1 (en) 2006-09-08 2008-02-01 Amgen Inc ISOLATED PROTEINS FROM LINK TO ACTIVINE TO HUMAN.
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
AU2016247166B2 (en) * 2006-11-02 2018-09-27 Acceleron Pharma Inc. ALK1 receptor and ligand antagonists and uses thereof
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
DK2087001T3 (en) * 2006-11-02 2017-02-06 Acceleron Pharma Inc ALK1 RECEPTOR AND LIGAND ANTAGONISTS AND APPLICATIONS THEREOF
US7947646B2 (en) 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
UY30994A1 (en) * 2007-04-02 2008-11-28 Amgen Fremont Inc ANTI-IGE ANTIBODIES
ITTV20070126A1 (en) 2007-07-16 2009-01-17 Luca Toncelli PROCEDURE AND EQUIPMENT FOR THE MANUFACTURE OF EFFET-VENATO SLABS
WO2009061807A2 (en) * 2007-11-09 2009-05-14 Genentech, Inc. Activin receptor-like kinase-1 compositions and methods of use
KR20100097684A (en) * 2007-11-12 2010-09-03 우드라이 파마 게엠베하 Axl antibodies
CA2712000A1 (en) * 2008-01-28 2009-08-06 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
US7855564B2 (en) * 2008-02-14 2010-12-21 Delaware Capital Formation, Inc. Acoustic wave device physical parameter sensor
EP2281002A2 (en) * 2008-04-25 2011-02-09 MorphoSys AG Anti-alk1 antibodies and uses thereof
KR20190128254A (en) * 2008-05-02 2019-11-15 악셀레론 파마 인코포레이티드 Methods and compositions based on alk1 antagonists for modulating angiogenesis and pericyte coverage
CA2724525A1 (en) * 2008-05-15 2009-11-19 Acceleron Pharma, Inc. Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
US8821870B2 (en) * 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
EA201100832A1 (en) 2008-11-26 2011-12-30 Амген Инк. OPTIONS OF POLYPEPTIDES OF ACTIVIN IIB RECEPTOR AND THEIR APPLICATION
WO2010126169A1 (en) * 2009-04-30 2010-11-04 協和発酵キリン株式会社 Pharmaceutical composition for preventing vascular disorders which comprises alk1 inhibitor as active ingredient
GB0915515D0 (en) 2009-09-04 2009-10-07 Ucl Business Plc Treatment of vasculoproliferative conditions
WO2011080209A2 (en) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
CA2803058C (en) 2010-06-25 2022-07-05 Vaccibody As Homodimeric protein constructs
EA201491231A8 (en) 2011-12-19 2015-01-30 Амген Инк. OPTIONS FOR ACTIVIN RECEPTOR POLYPEPTIDES AND THEIR APPLICATION
AR090410A1 (en) 2012-01-09 2014-11-12 Covx Technologies Ireland Ltd MUTANT ANTIBODIES AND CONJUGATION OF THE SAME
WO2013155447A1 (en) 2012-04-13 2013-10-17 Children's Medical Center Corporation Tiki inhibitors
UY35148A (en) 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
EA201591423A1 (en) * 2013-02-01 2016-01-29 Санта Мария Биотерапевтикс, Инк. INTRODUCTION OF ANTIBODIES TO ACTIVINE-A TO PATIENTS
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
EP2787006B1 (en) 2013-04-02 2018-02-28 Miltenyi Biotec GmbH Anti-CD8 antibody which binding is Ca2+ dependent
CA2923145A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015175861A1 (en) 2014-05-16 2015-11-19 Amgen Inc. Assay for detecting th1 and th2 cell populations
WO2016054053A2 (en) * 2014-09-29 2016-04-07 Duke University Hiv-1 antibodies and uses thereof (adcc and bispecific abs)
GB201503438D0 (en) 2015-02-27 2015-04-15 Ucl Business Plc Antibodies
SG11201707815RA (en) 2015-06-05 2017-12-28 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
KR101983013B1 (en) * 2015-09-25 2019-05-28 동우 화인켐 주식회사 Film touch sensor and method for manufacturing the same
JP2017077830A (en) * 2015-10-21 2017-04-27 Ｋｙｂ株式会社 Electric power steering device
EP3413912A4 (en) * 2016-02-11 2019-09-25 The Johns Hopkins University Compositions and methods for targeting activin signaling to treat cancer
RU2615908C1 (en) * 2016-05-16 2017-04-11 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Method for murine melanoma lymphatic and hematogenous metastasis b16 simulation for nonlinear white rats
CN109689090B (en) 2016-08-05 2023-12-26 免疫医疗有限责任公司 anti-O2 antibodies and uses thereof
SG11201903063UA (en) 2016-10-19 2019-05-30 Medimmune Llc Anti-o1 antibodies and uses thereof
CA3056011A1 (en) 2017-03-14 2018-09-20 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
CN111954719A (en) 2018-03-26 2020-11-17 美国安进公司 Total defucosylated glycoforms of antibodies produced in cell culture
WO2021062372A1 (en) 2019-09-26 2021-04-01 Amgen Inc. Methods of producing antibody compositions
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
MX2023004364A (en) 2020-10-15 2023-05-03 Amgen Inc Relative unpaired glycans in antibody production methods.
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN115746142A (en) * 2021-09-03 2023-03-07 开拓药业(广东)有限公司 anti-ALK-1/anti-VEGF bispecific antibody and application thereof
CA3233279A1 (en) 2021-10-05 2023-04-13 Amagen, Inc. Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968752A (en) * 1995-08-14 1999-10-19 Creative Biomolecules, Inc. Method for identifying an OP-1 analog which binds an ALK-1 receptor
US20030152514A1 (en) * 2001-12-28 2003-08-14 Jean Gudas Methods for using anti-MUC18 antibodies
US20050054019A1 (en) * 2003-08-04 2005-03-10 Michaud Neil R. Antibodies to c-Met

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
JP2532858B2 (en) 1985-04-01 1996-09-11 セルテツク リミテツド Transformed myeloma cell line
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
JPH0341802A (en) 1989-07-07 1991-02-22 Ngk Spark Plug Co Ltd Temperature compensation type microwave strip line filter
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ATE185601T1 (en) 1990-07-10 1999-10-15 Cambridge Antibody Tech METHOD FOR PRODUCING SPECIFIC BONDING PAIRS
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (en) 1990-08-29 1997-12-16 Genpharm Int PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES.
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69129154T2 (en) 1990-12-03 1998-08-20 Genentech Inc METHOD FOR ENRICHING PROTEIN VARIANTS WITH CHANGED BINDING PROPERTIES
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
IE921169A1 (en) 1991-04-10 1992-10-21 Scripps Research Inst Heterodimeric receptor libraries using phagemids
DE4122599C2 (en) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid for screening antibodies
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
ATE181571T1 (en) 1991-09-23 1999-07-15 Medical Res Council METHODS FOR PRODUCING HUMANIZED ANTIBODIES
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5679666A (en) 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5770592A (en) 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
CA2129663C (en) 1992-02-06 2005-07-05 James S. Huston Biosynthetic binding protein for cancer marker
AU675661B2 (en) 1992-07-24 1997-02-13 Abgenix, Inc. Generation of xenogeneic antibodies
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US7592428B1 (en) 1992-11-17 2009-09-22 Ludwig Institute For Cancer Research Antibodies which bind specifically to activin receptor like kinases
US6692925B1 (en) * 1992-11-17 2004-02-17 Ludwig Institute For Cancer Research Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
EP0677104B1 (en) 1992-11-17 2003-03-19 Ludwig Institute For Cancer Research Activin receptor-like kinases, proteins having serine threonine kinase domains and their use
PT804070E (en) 1993-03-09 2000-11-30 Genzyme Corp ISOLATION OF COMPONENTS OF INTEREST FROM MILK.
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5608082A (en) 1994-07-28 1997-03-04 Agouron Pharmaceuticals, Inc. Compounds useful as antiproliferative agents and GARFT inhibitors
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US5633272A (en) 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2218489A1 (en) 1995-04-21 1996-10-24 Aya Jakobovits Generation of large genomic dna deletions
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US5663272A (en) 1995-12-22 1997-09-02 Bayer Corporation Allophanate-modified diphenylmethane diisocyanates and processes for their production and use
KR100489174B1 (en) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-anilinoquinazoline derivatives
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
US6180651B1 (en) 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
NZ331542A (en) 1996-04-12 1999-07-29 Searle & Co Substituted benzenesulfonamide derivatives as prodrugs of cox-2 inhibitors and salts thereof that are useful in treating inflammation and inflammation-related disorders
DE19616523A1 (en) * 1996-04-25 1997-11-06 Basf Ag Polymerization catalysts with beta-diketiminate ligands
BR9709974A (en) 1996-06-27 1999-08-10 Pfizer 2- (2-Oxo-Ethidylene) -imidazolidin-4-one derivatives and their use as farnesyl protein transferase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
BR9710362A (en) 1996-07-13 1999-08-17 Glaxo Group Ltd Pharmaceutical formulation compound uses a compound processes of treatment of a human or animal suffering from a mediated by abnormal activity of protein tyrosine kinase and for the preparation of a compound
ID19609A (en) 1996-07-13 1998-07-23 Glaxo Group Ltd HETEROSICLIC COMPOUNDS
KR100371620B1 (en) 1996-07-18 2003-05-09 머크 프로스트 캐나다 앤드 캄파니 Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1500329T3 (en) 1996-12-03 2012-07-09 Amgen Fremont Inc Human antibodies that specifically bind TNF-alpha
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
JP2002512624A (en) 1997-05-21 2002-04-23 バイオベーション リミテッド Method for producing non-immunogenic protein
EP0984692A4 (en) 1997-05-30 2001-02-21 Merck & Co Inc Novel angiogenesis inhibitors
DE69838172T2 (en) 1997-08-22 2008-04-10 Astrazeneca Ab OXINDOLYLCHINAZOLE DERIVATIVES AS ANGIOGENESEHEMMER
CO4960662A1 (en) 1997-08-28 2000-09-25 Novartis Ag CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND THEIR DERIVATIVES
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
CN1280580A (en) 1997-11-11 2001-01-17 辉瑞产品公司 Thienopyrimidine and thienopyridine derivatives useful as anti-cancer agents
JPH11236333A (en) 1997-12-30 1999-08-31 Pfizer Prod Inc Imidazolin-4-one derivative as anticancer agent
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
AU2978899A (en) 1998-03-03 1999-09-20 Abgenix, Inc. Cd147 binding molecules as therapeutics
AU3092899A (en) * 1998-03-13 1999-09-27 Ludwig Institute For Cancer Research Alk-1 responds to tgf-beta and signals through smad-1 and smad-5
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
SK287132B6 (en) 1998-05-29 2009-12-07 Sugen, Inc. Pharmaceutical composition containing pyrrole substituted 2-indolinone, kit containing mentioned composition and use pyrrole substituted 2-indolinone
UA60365C2 (en) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Isothiazole derivatives, a method for preparing thereof, a pharmaceutical composition and a method for treatment of hyperproliferative disease of mammal
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
EP1107962B1 (en) 1998-08-27 2005-02-23 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
AU4925499A (en) 1998-08-27 2000-03-21 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
PT2112166T (en) 1998-12-23 2019-01-30 Pfizer Human monoclonal antibodies to ctla-4
JP3270834B2 (en) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク Heteroaromatic bicyclic derivatives useful as anticancer agents
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EP1150973B1 (en) 1999-02-11 2005-06-15 Pfizer Products Inc. Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
US5998206A (en) * 1999-02-23 1999-12-07 Isis Pharmaceuticals Inc. Antisense inhibiton of human G-alpha-12 expression
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
DE60022383T2 (en) 1999-11-05 2006-03-09 Amada Co., Ltd., Isehara BEND PRESSURE AND METHOD FOR CONTROLLING A BIDIRECTIONAL FLUID PUMP OF A HYDRAULIC CYLINDER OF A BENDING PED
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
UA75055C2 (en) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Benzoimidazole derivatives being used as antiproliferative agent, pharmaceutical composition based thereon
TR200400342T4 (en) 1999-11-30 2004-03-22 Pfizer Products Inc. Farnezil quinoline derivatives to inhibit protein transferase.
JP2003516746A (en) * 1999-12-15 2003-05-20 リサーチ ディベロップメント ファンデーション Beta-glycans as inhibin receptors and their use
BRPI0108394B8 (en) 2000-02-15 2021-05-25 Upjohn Co substituted pyrrole 2-indolinone protein kinase inhibitors, their salts and pharmaceutical compositions comprising the same
US6584504B1 (en) 2000-05-26 2003-06-24 Networks Associates Technology, Inc. Method and apparatus for monitoring internet traffic on an internet web page
PL359557A1 (en) 2000-06-22 2004-08-23 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth
CA2420192A1 (en) 2000-09-20 2002-03-28 Human Genome Sciences, Inc. 21 human secreted proteins
MY143465A (en) 2001-01-05 2011-05-13 Pfizer Antibodies to insulin-like growth factor i receptor
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
PT1391464E (en) * 2001-04-27 2007-11-15 Kirin Pharma Kk Anti-cd40 monoclonal antibody
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
DE60226641D1 (en) 2001-12-03 2008-06-26 Amgen Fremont Inc ANTIBODY CATEGORIZATION BASED ON BINDING CHARACTERISTICS
CA2467738A1 (en) * 2001-12-03 2003-06-12 Abgenix, Inc. Antibodies against carboxic anhydrase ix (ca ix) tumor antigen
PA8580301A1 (en) 2002-08-28 2005-05-24 Pfizer Prod Inc NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS
WO2004050683A2 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
CN103087940B (en) 2005-02-04 2015-05-13 Cp凯尔科美国公司 Targeted gene deletions for polysaccharide slime formers
TWI541253B (en) * 2005-09-07 2016-07-11 艾默根佛蒙特有限公司 Human monoclonal antibodies to activin receptor-like kinase-1
JP6943759B2 (en) 2017-12-28 2021-10-06 株式会社東海理化電機製作所 Shift device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968752A (en) * 1995-08-14 1999-10-19 Creative Biomolecules, Inc. Method for identifying an OP-1 analog which binds an ALK-1 receptor
US20030152514A1 (en) * 2001-12-28 2003-08-14 Jean Gudas Methods for using anti-MUC18 antibodies
US20050054019A1 (en) * 2003-08-04 2005-03-10 Michaud Neil R. Antibodies to c-Met

Also Published As

Publication number Publication date
SI1933871T1 (en) 2013-10-30
US20120052074A1 (en) 2012-03-01
UY29783A1 (en) 2007-04-30
AR055152A1 (en) 2007-08-08
HK1219488A1 (en) 2017-04-07
EP2447283B1 (en) 2015-07-15
HUE025608T2 (en) 2016-03-29
MY164457A (en) 2017-12-15
AU2006297571A1 (en) 2007-04-12
CN107056943A (en) 2017-08-18
CN107056943B (en) 2021-06-08
CA2621371A1 (en) 2007-04-12
UA94060C2 (en) 2011-04-11
PE20080035A1 (en) 2008-01-30
TNSN08080A1 (en) 2009-07-14
CL2010000096A1 (en) 2010-06-25
EP2447283A2 (en) 2012-05-02
KR101390127B1 (en) 2014-05-13
EP1933871A2 (en) 2008-06-25
AP2013006963A0 (en) 2013-07-31
TW201511773A (en) 2015-04-01
JP2014218514A (en) 2014-11-20
US7537762B2 (en) 2009-05-26
SI2447283T1 (en) 2015-12-31
NZ566774A (en) 2011-11-25
LT2960253T (en) 2018-10-10
ES2421146T3 (en) 2013-08-29
TW201431883A (en) 2014-08-16
JP5161777B2 (en) 2013-03-13
IL189642A0 (en) 2008-06-05
TW201030017A (en) 2010-08-16
ES2546069T3 (en) 2015-09-18
JP2012228251A (en) 2012-11-22
AR107003A2 (en) 2018-03-07
SI2960253T1 (en) 2018-10-30
NO20081718L (en) 2008-06-03
WO2007040912A2 (en) 2007-04-12
CR20130351A (en) 2013-08-13
JP5947840B2 (en) 2016-07-06
ES2681656T3 (en) 2018-09-14
EA201300320A1 (en) 2014-02-28
CN101517068B (en) 2017-02-08
EA018453B1 (en) 2013-08-30
AU2006297571A2 (en) 2008-05-01
IL189642A (en) 2013-06-27
NL1032452A1 (en) 2007-03-08
ME00501B (en) 2011-10-10
TWI453218B (en) 2014-09-21
DOP2006000195A (en) 2017-08-15
EA200800759A1 (en) 2008-08-29
ZA200802971B (en) 2009-10-28
EP2447283A3 (en) 2012-06-20
CY1120794T1 (en) 2019-12-11
EP3381945A1 (en) 2018-10-03
PL1933871T3 (en) 2013-09-30
KR101536487B1 (en) 2015-07-13
AU2006297571B2 (en) 2012-03-15
HUE038941T2 (en) 2018-12-28
PL2960253T3 (en) 2018-11-30
EP1933871B1 (en) 2013-04-24
PT2960253T (en) 2018-07-31
PL2447283T3 (en) 2015-12-31
US20100197005A1 (en) 2010-08-05
IL218429A0 (en) 2012-04-30
PT1933871E (en) 2013-07-17
CA2621371C (en) 2018-05-15
CR9819A (en) 2008-12-03
PT2447283E (en) 2015-10-08
RS54393B1 (en) 2016-04-28
US9221915B2 (en) 2015-12-29
EP2960253A1 (en) 2015-12-30
TW200801043A (en) 2008-01-01
NL1032452C2 (en) 2008-01-18
EP2960253B1 (en) 2018-06-06
KR20140004261A (en) 2014-01-10
DK1933871T3 (en) 2013-07-08
TW201311728A (en) 2013-03-16
CR20140239A (en) 2014-06-13
DK2447283T3 (en) 2015-08-31
BRPI0615766A2 (en) 2009-06-16
HK1169999A1 (en) 2013-02-15
JP2009506791A (en) 2009-02-19
GEP20125398B (en) 2012-02-27
CN101517068A (en) 2009-08-26
JP5833978B2 (en) 2015-12-16
US20070065444A1 (en) 2007-03-22
HN2006031275A (en) 2010-10-29
TWI569807B (en) 2017-02-11
US8080646B2 (en) 2011-12-20
KR20080045715A (en) 2008-05-23
MA29843B1 (en) 2008-10-03
RS20080103A (en) 2009-07-15
EP1933871A4 (en) 2009-10-28
KR101536506B1 (en) 2015-07-14
EP3381945B1 (en) 2020-08-19
DK2960253T3 (en) 2018-08-13
KR20130042648A (en) 2013-04-26
TWI370137B (en) 2012-08-11
AP2008004388A0 (en) 2008-04-30
AP2723A (en) 2013-08-31
TWI541253B (en) 2016-07-11
GT200600406A (en) 2007-07-13
TWI389919B (en) 2013-03-21

Similar Documents

Publication Publication Date Title
WO2007040912A3 (en) Human monoclonal antibodies to activin receptor-like kinase-1
WO2006114704A3 (en) P-cadherin antibodies
WO2005067620A3 (en) ANTIBODIES TO MAdCAM
WO2006116269A3 (en) Antibodies to myostatin
WO2003040170A3 (en) Antibodies to cd40
WO2005030124A3 (en) Antibodies to m-csf
WO2008019290A3 (en) Human antibodies to erbb 2
WO2008079246A3 (en) Cd44 antibodies
WO2008060331A3 (en) Antibodies to sars coronavirus

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680041490.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 189642

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 866/KOLNP/2008

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2621371

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12008500558

Country of ref document: PH

Ref document number: 2008530231

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: P-2008/0103

Country of ref document: RS

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008030403

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: AP/P/2008/004388

Country of ref document: AP

Ref document number: MX/a/2008/003351

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006297571

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: CR2008-009819

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: DZP2008000163

Country of ref document: DZ

Ref document number: 1020087006587

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 566774

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006824915

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200800759

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 10627

Country of ref document: GE

Ref document number: 08034643A

Country of ref document: CO

Ref document number: 08034643

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2006297571

Country of ref document: AU

Date of ref document: 20060906

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0615766

Country of ref document: BR

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 218429

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: CR2013-000351

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 1020137033726

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: CR2014-000239

Country of ref document: CR